

Resource Summary Report

Generated by SPARC SAWG on Aug 25, 2026

PerCP/Cyanine5.5 anti-human CD19

RRID:AB_2275547

Type: Antibody

Proper Citation

BioLegend Cat# 302229, RRID:AB_2275547

Antibody Information

URL: http://antibodyregistry.org/AB_2275547

Proper Citation: BioLegend Cat# 302229, RRID:AB_2275547

Target Antigen: CD19

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-human CD19

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: Clone HIB19

Antibody ID: AB_2275547

Vendor: BioLegend

Catalog Number: 302229

Alternative Catalog Numbers: 302230

Record Creation Time: 20250820T030829+0000

Record Last Update: 20250820T152723+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-human CD19.

No alerts have been found for PerCP/Cyanine5.5 anti-human CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Andreas N, et al. (2026) Accumulation of Siglec10+CX3CR1+ Macrophages in the Tumor Microenvironment of Glioblastomas. European journal of immunology, 56(4), e70180.

Wientjens C, et al. (2025) Tolerance to ferroptosis facilitates lipid metabolism and pathogenic type 2 immunity in allergic airway inflammation. Immunity.

Chandra V, et al. (2024) Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation. Cancer cell, 42(1), 85.

Nelde A, et al. (2023) Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. Blood cancer discovery, 4(6), 468.

Jalbert E, et al. (2023) Comparative immune responses to Mycobacterium tuberculosis in people with latent infection or sterilizing protection. iScience, 26(8), 107425.

Seow J, et al. (2022) ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. Cell reports, 39(5), 110757.

Graham C, et al. (2021) Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Immunity, 54(6), 1276.

K??rner C, et al. (2017) HIV-1-Mediated Downmodulation of HLA-C Impacts Target Cell Recognition and Antiviral Activity of NK Cells. Cell host & microbe, 22(1), 111.